Conference Correspondent

Ibrutinib Treatment in Waldenström’s Macroglobulinemia: Follow-Up Efficacy and Safety from the iNNOVATE Study

Conference Correspondent - ASH 2018 - CLL

Prior reports have indicated that the combination of ibrutinib and rituximab showed sustained responses and a manageable toxicity profile in rituximab-refractory Waldenström’s macroglobulinemia (Dimopoulos MA, et al. Lancet Oncol. 2016). Here, researchers present follow-up findings from the phase 3 iNNOVATE study.

There were 3 treatment arms in the study. Patients in the randomized part of the trial received prior rituximab therapy and required a response to their last rituximab-based regimen. These patients were randomized to either daily 420 mg of ibrutinib plus rituximab (IR) or placebo plus rituximab (R) at a dose of 375 mg/m2 per week intravenously at weeks 1 to 4 and 17 to 20. In an open-label substudy, patients who failed to achieve a minor response or better, or relapsed within 12 months of their last rituximab-containing therapy, received daily 420 mg of ibrutinib until disease progression or unacceptable toxicity.

With extended follow-up and a median duration of treatment of 33.4 months, overall response rates (ORRs) were 95% with IR versus 48% with R (P <.0001), respectively. With continued IR treatment, 25% of patients achieved a very good partial response compared with only 3% in the R arm. Median progression-free survival (PFS) was not reached with IR versus 20.3 months with R (hazard ratio, 0.22 [0.12-0.39]; P <.0001). At 36 months, PFS was 76% for patients receiving IR treatment versus 31% for R. The 36-month overall survival (OS) rates were 93% for IR and 90% for R, a nonsignificant difference.

Completion of treatment was 93% among patients receiving IR compared with 71% in patients receiving R. Overall, grade ≥3 adverse events (AEs) occurred in 49% of patients in the IR arm and 42% in the R arm.

In the open-label substudy, 31 patients received single-agent ibrutinib. In this group, with longer follow-up, median PFS was 41 months, estimated 36-month PFS was 61%, ORR was 90%, and estimated 36-month OS was 84%. Median duration of ibrutinib treatment was 38.4 months, with no major hemorrhagic or atrial fibrillation events reported. Grade ≥3 AEs occurred in 77% of patients; however, no fatal AEs were reported.

Researchers concluded that IR showed continued superiority over R in treatment-naïve and previously treated patients with Waldenström’s macroglobulinemia, regardless of genotypic factors. In both relevant study arms, ibrutinib had a manageable safety profile and no new safety signals were identified with longer follow-up.

Buske C, et al. ASH 2018. Abstract 149.

Related Items
Prognostic Testing and Treatment Approaches in Patients with CLL: Interim Analysis of the informCLL Real-World Registry
Conference Correspondent published on December 4, 2018 in ASH 2018 - CLL
Acalabrutinib in Patients with Relapsed/Refractory and High-Risk, Treatment-Naïve CLL
Conference Correspondent published on December 4, 2018 in ASH 2018 - CLL
Cost-Effectiveness Comparison of Ibrutinib, Chemotherapy, and Chemoimmunotherapy in First-Line Treatment of CLL
Conference Correspondent published on December 4, 2018 in ASH 2018 - CLL
ECOG-ACRIN Cancer Research Group: Phase 3 Study of Ibrutinib-Based Therapy in Untreated Younger Patients with CLL
Conference Correspondent published on December 4, 2018 in ASH 2018 - CLL
Dual Inhibition of Bruton’s Tyrosine Kinase and BCL2: A Promising Therapeutic Strategy for Myeloid and Lymphoid Leukemias
Conference Correspondent published on December 2, 2018 in ASH 2018 - CLL
Last modified: December 2, 2018
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME